Results 11 to 20 of about 4,930 (199)

Midodrine and clinical outcomes in patients on maintenance hemodialysis. [PDF]

Sci Rep
Patients on hemodialysis often experience intradialytic hypotension (IDH), contributing to increased cardiovascular disease and mortality. Midodrine, an α-1 adrenergic receptor agonist, is commonly prescribed for IDH treatment or prevention. However, the
Jeon J, Lim YJ, Kim BY, Choi JY, Do JY, Lee JE, Kang SH.   +6 more
europepmc   +2 more sources

The effects of midodrine on patients with liver cirrhosis and refractory ascites: a randomized controlled trial [PDF]

African Journal of Gastroenterology and Hepatology, 2023
Background: Splanchnic vasodilation is a significant contributor to the development of ascites in cirrhotic patients. So, midodrine, an alpha-one agonist, may improve circulatory abnormality in cirrhotic patients via its vasoconstrictive action, thus ...
Essam Aboelnasr, Sahar Elyamani, Amira Ahmed, Samah Soliman   +3 more
doaj   +1 more source

Hemodynamic Effects of an Increased Midodrine Dosing Frequency

Critical Care Explorations, 2021
Objectives:. In practice, midodrine has been used to reduce IV vasopressor requirements and decrease ICU length of stay. However, recent publications have failed to show clinical success when midodrine was administered every 8 hours.
Shea A. Macielak, PharmD, Nicholas J. Vollmer, PharmD, Natalie A. Haddad, PharmD, Christoph G. S. Nabzdyk, MD, Scott D. Nei, PharmD   +4 more
doaj   +1 more source

Need for Pretransplant Midodrine Does Not Negatively Impact Simultaneous Liver-kidney Transplant Outcomes

Transplantation Direct, 2021
Background. Midodrine is often needed pretransplant to improve hemodynamics in simultaneous liver-kidney transplant candidates. Previous research has shown that patients requiring midodrine before kidney transplant alone have increased posttransplant ...
Pranab M. Barman, MD, Lindsay Y. King, MD, Carl L. Berg, MD, Alice Parish, MSPH, Donna Niedzwiecki, PhD, Andrew S. Barbas, MD, Lisa McElroy, MD, Yuval A. Patel, MD   +7 more
doaj   +1 more source

Impact of COVID‑19 infection on subsequent prescriptions of autonomic dysfunction pharmacotherapy: a nationwide propensity‑score‑matched Cohort study in Japan. [PDF]

Ann Med
Background Autonomic dysfunction, including orthostatic hypotension and postural tachycardia syndrome, has emerged as a COVID-19 complication.
Miyamori D, Ito M.
europepmc   +2 more sources

Stimulation of Alpha-1-Adrenergic Receptor Ameliorates Obesity-Induced Cataracts by Activating Glycolysis and Inhibiting Cataract-Inducing Factors [PDF]

Endocrinology and Metabolism, 2022
Background Obesity, the prevalence of which is increasing due to the lack of exercise and increased consumption of Westernized diets, induces various complications, including ophthalmic diseases. For example, obesity is involved in the onset of cataracts.
Yong-Jik Lee, Yoo-Na Jang, Hyun-Min Kim, Yoon-Mi Han, Hong Seog Seo, Youngsub Eom, Jong-suk Song, Ji Hoon Jeong, Tae Woo Jung   +8 more
doaj   +1 more source

Calcitonin gene-related peptide predicts therapeutic response to midodrine hydrochloride in children with vasovagal syncope

Frontiers in Neuroscience, 2022
The vasoconstriction agent midodrine hydrochloride is a vital treatment for pediatric patients diagnosed with vasovagal syncope (VVS), although the efficacy is variable.
Lintian Li, Huacai Zhao, Xiuxiu Ma, Fuyong Jiao, Jing Lin   +4 more
doaj   +1 more source

The Use of Midodrine as an Adjunctive Therapy to Liberate Patients from Intravenous Vasopressors: A Systematic Review and Meta-analysis of Randomized Controlled Studies

Cardiology and Therapy, 2023
Background Studies evaluating the role of midodrine as an adjunctive therapy to liberate patients with shock from intravenous (IV) vasopressors have yielded mixed results.
Mohamed Hamed, Sheref A. Elseidy, Ahmed Elkheshen, Jamal Maher, Adel Elmoghrabi, Ahmed Zaghloul, Andrew Panakos, Sidakpal Panaich, Marwan Saad, Ayman Elbadawi   +9 more
doaj   +1 more source

Oral Midodrine Administration During the First 24 Hours of Sepsis to Reduce the Need of Vasoactive Agents: Placebo-Controlled Feasibility Clinical Trial

Critical Care Explorations, 2021
Objectives:. Our preliminary data and observational studies suggested an increasing “off label” use of oral midodrine as a vasopressor sparing agent in various groups of critically ill patients, including those with sepsis.
Amos Lal, MBBS, FACP, Vrinda Trivedi, MBBS, Mahrukh S. Rizvi, MD, Amy Amsbaugh, RRT, LRT, Melissa K Myers, MD, Khaled Saleh, MD, Rahul Kashyap, MBBS, MBA, Ognjen Gajic, MD, MSc, FCCP, FCCM   +7 more
doaj   +1 more source

Norepinephrine is More Effective Than Midodrine/Octreotide in Patients With Hepatorenal Syndrome-Acute Kidney Injury: A Randomized Controlled Trial

Frontiers in Pharmacology, 2021
Background: Terlipressin is the first-line pharmacological treatment for hepatorenal syndrome. When terlipressin is unavailable, midodrine/octreotide or norepinephrine, with albumin, represent the alternative treatments. The comparative efficacy of these
Eman Ibrahim El-Desoki Mahmoud, Doaa H Abdelaziz, Doaa H Abdelaziz, Sherief Abd-Elsalam, Noha O. Mansour   +4 more
doaj   +1 more source